INTERNATIONAL PATENT: NATIONAL CANCER CENTER, 国立研究開発法人国立がん研究センター FILES APPLICATION FOR "ANTIBODY AND FRAGMENT THEREOF THAT BIND TO CD320 AND ANTIBODY-DRUG CONJUGATE INCLUDING SAID ANTIBODY"

GENEVA, Feb. 17 -- NATIONAL CANCER CENTER (1-1, Tsukiji 5-chome, Chuo-ku, Tokyo1040045), 国立研究開発法人国立がん研究センター (東京都中央区築地五丁目１番１号) filed a patent application (PCT/JP2025/028028) for "ANTIBODY AND FRAGMENT THEREOF THAT BIND TO CD320, AND ANTIBODY-DRUG CONJUGATE INCLUDING SAID ANTIBODY" on Aug 06, 2025. With publication no. WO/2026/034573, the details related to the patent application was published on Feb 12, 2026.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, ...